BioNexus Gene Lab posted a net loss attributable to common shareholders of $286,451, narrowing 53.51% year over year.
Revenue fell 96.63% to $76,156, reflecting a 96.65% drop at Chemrex to $75,506.
Operating loss narrowed to $282,396 from the prior-year quarter, while total gross profit slid to $12,982.
Liquidity and business updates
Cash and cash equivalents totaled $2.39 million at June 30, 2026; total liquidity was $3.5 million.
VitaGuard had not generated revenue as of June 30, 2026; GeneMatrix enterprise build completed internal workflow testing, targeting an initial Q3 2026 release.
BGLC•
